

The implant for IMPLANON NXT[®] is shown in the image below. Actual implant length is 4 cm.

IMPLANON NXT[®]

- a **non-uterine LARC** that is
>99% effective^{1,*}




LARC = long-acting reversible contraception

¹Less than 1 pregnancy per 100 women who used IMPLANON NXT[®] for 1 year.²

IMPLANON NXT[®] is indicated for contraception. Safety and efficacy have been established in women between 18 and 40 years of age.

A LARC that doesn't go in
the uterus¹



Flexible rod¹

- The IMPLANON NXT[®] rod is around 4 cm long and 2 mm in diameter¹
- It's inserted subdermally just under the skin of the inner non-dominant upper arm¹
- After insertion, both you and your patient should be able to feel the rod just under the skin¹



**In clinical trials[†], mean insertion
time was under 1 minute^{4,††}**

- Insertion:
 - » Can be performed by any qualified healthcare provider who is familiar with the procedure³
 - » Is done using anesthetic spray or by injecting 2 ml of 1%¹ lidocaine just under the skin along the planned insertion site¹

**Over
99%
effective^{1,*}**

**With pregnancy prevention for
up to 3 years^{1,†††}**

- No daily, weekly, or monthly dosing^{1,2}

¹Less than 1 pregnancy per 100 women who used IMPLANON NXT[®] for 1 year.²

[†] **Study design:** In a clinical study evaluating the insertion characteristics of the applicator for IMPLANON NXT[®]: Out of 301 insertions of the IMPLANON NXT[®] implant, the mean insertion time (from the removal of the protective cap of the applicator until retraction of the needle from the arm) was 27.9 ± 29.3 seconds.⁴

^{††} From the removal of protective cap of the applicator until retraction of the needle from the arm.

^{†††} IMPLANON NXT[®] must be removed by the end of the third year.¹

References:

1. Implanon NXT[®] CCDS. Organon Inc., February 22, 2022.
2. Implanon NXT[®] Prescribing Information. Organon Malaysia, September 2021.
3. American College of Obstetricians and Gynecologists. Long-acting reversible contraception (LARC): intrauterine device (IUD) and implant. Accessed June 9, 2022. <https://www.acog.org/womens-health/faqs/long-acting-reversible-contraception-iud-and-implant>
4. Mansour D, Mommers E, Teede H, et al. Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an open-label, noncontrolled, multicenter trial. *Contraception*. 2010;82(3):243-249.

Selected Safety Information for Implanon NXT[®] (etonogestrel)

COMPOSITION: Each radiopaque implant contains 68 mg of etonogestrel. **THERAPEUTIC INDICATIONS:** Contraception. **DOSE AND ADMINISTRATION:** Pregnancy should be excluded before insertion of Implanon NXT[®]. Healthcare professionals (HCPs) are strongly recommended to participate in a training session to become familiar with the use of the Implanon NXT[®] applicator and the techniques for insertion and removal of the Implanon NXT[®] implant and where appropriate, request supervision prior to inserting or removing the implant. Subdermal insertion. No preceding hormonal contraceptive use in the past mth: Insert on day 1 & 5 of the menstrual cycle. Changing from combined oral contraceptive (COG), vaginal ring or transdermal patch: Insert preferably on the day after last active COC tab, but at the latest on the day following the usual tab-free interval or last placebo COG tab. Changing from progestagen-only method [pill, injectable, implant or intrauterine system (IUS)] Injectable contraceptives: Insert when the next injection would be due. Pill: Insert within 24 hr any day after last pill. Implant or IUS: Insert on the same day of removal. Post 1st-trimester abortion Insert within 5 days following 1st trimester abortion or miscarriage. Post 2nd-trimester abortion Insert between day 21-28 following 2nd trimester abortion or miscarriage. Postpartum with breastfeeding: Insert after 4th postpartum week. Postpartum without breastfeeding: Insert between 21-28 days postpartum. **CONTRAINDICATIONS:** Progestagen-only contraceptives should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during the use of Implanon NXT[®], the product should be stopped immediately. · Known or suspected pregnancy. · Active venous thromboembolic disorder. · Known or suspected sex steroid sensitive malignancies · Presence or history of liver tumours (benign or malignant). · Presence or history of severe hepatic disease as long as liver function values have not returned to normal. · Undiagnosed vaginal bleeding. · Hypersensitivity to the active substance or to any of the excipients of Implanon NXT[®]. **SPECIAL WARNINGS & PRECAUTIONS:** If any of the conditions/risk factors mentioned below is present, the benefits of progestagen use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start with Implanon NXT[®]. · Carcinoma of the Breast · Liver Disease · Thrombotic and Other Vascular Events · Elevated Blood Pressure · Carbohydrate and Lipid Metabolic Effects · Chloasma · Body Weight · Complications of Insertion · Ovarian Cysts · Ectopic Pregnancies · Other Conditions The following conditions have been reported both during pregnancy and during sex steroid use, but an association with the use of progestagens has not been established: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; hemolytic uraemic syndrome; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss and (hereditary) angioedema. **ADVERSE REACTIONS:** During the use of Implanon NXT, women are likely to have changes in their menstrual bleeding pattern. These may include changes in bleeding frequency (absent, less, more frequent or continuous), intensity (reduced or increased) or duration. Possibly related undesirable effects reported in clinical trials: Vaginal infection; headache; acne; breast pain & tenderness, irregular menstruation; increased weight. Increased appetite; affect lability, depression, nervousness, decreased libido; dizziness; hot flush; abdominal pain, nausea, flatulence; alopecia; dysmenorrhea, ovarian cyst; implant site pain & reaction, fatigue, flu-like illness, pain; decreased weight.

Before initiating therapy, please consult the full Prescribing Information.

This material is only for Healthcare Professionals.



Organon Malaysia Sdn. Bhd.

Mercu 2, Level 40, Office 39-W022, No 3 Jalan Bangsar, KL Eco City,

59200 Kuala Lumpur, Wilayah Persekutuan, Malaysia.

Tel No.: +603-2386 2000 | Fax No.: +603-2386 2100

© 2023 Organon group of companies. All rights reserved.

MY-XPL-110041 Jan/2023